The global viral vectors-based gene therapy for non-human primates market is poised for significant growth, driven by advancements in gene therapy research and increasing demand for preclinical studies. Key drivers to viral vectors-based gene therapy for non-human primates industry include the rising prevalence of genetic disorders, infectious diseases, and oncological conditions, necessitating effective therapeutic solutions.
The integration of innovative technologies such as adeno-associated viral (AAV) vectors and CRISPR gene editing is enhancing the precision and efficacy of gene delivery systems. Additionally, the expansion of collaborative research efforts among pharmaceutical companies, academic institutions, and contract research organizations (CROs) is accelerating the development of viral vector-based therapies.
However, challenges such as regulatory hurdles, ethical concerns regarding the use of NHPs, and biosafety issues remain. Despite these obstacles, opportunities exist in emerging markets and advancements in vector technologies, which are likely to drive further growth in this dynamic sector.
Overall, the viral vectors-based gene therapy for non-human primates market is well-positioned to contribute significantly to the future of gene therapy and vaccine development, ultimately improving health outcomes worldwide.
Increased research and development activities for viral vectors-based gene therapy for non-human primates (NHPs) are expected to drive the growth of the global viral vectors-based gene therapy for non-human primates market over the forecast period.
Continuous advancements in gene therapy research are enhancing the effectiveness and safety of viral vectors. These improvements are crucial for developing innovative therapeutic solutions, particularly in preclinical studies involving NHPs, which are essential for validating new therapies before human trials. The increased focus on gene therapy is leading to a greater demand for effective viral vectors tailored for NHP studies, thereby expanding the viral vectors-based gene therapy for non-human primates market.
As the field of gene therapy evolves, there is an increasing need for preclinical studies to assess the safety and efficacy of new therapies. Non-human primates serve as critical models due to their genetic and physiological similarities to humans. This growing demand for NHPs in translational research is expected to significantly boost the viral vectors-based gene therapy for non-human primates market.
For instance, in March 2022, researchers at Mass Eye and Ear have developed a promising approach regarding delivery of genetic material to the inner ear of non-human primates, paving the way for potential treatments for hearing loss and vestibular disorders. The team's findings, published in Nature Communications, demonstrate the effectiveness of combining the synthetic adeno-associated virus (AAV) vector Anc80L65 with a novel surgical technique called transmastoid posterior tympanotomy to efficiently target the inner ear.
The surgical procedure, which involves accessing the round window membrane of the inner ear through a small fenestra in the oval window, was well-tolerated by the non-human primates. These findings demonstrate the potential of this gene therapy approach to effectively target the inner ear and provide hope for the development of treatments for millions of individuals affected by hearing disorders globally.
| Attribute | Detail |
|---|---|
| Viral Vectors-based Gene Therapy for Non-human Primates Market Drivers |
|
The potential uses of gene therapy have increased due to developments in the understanding of genetic illnesses and the creation of focused medicines. Therapeutic genes can now be precisely delivered and expressed; thanks to viral vectors, thereby improving the efficacy of treatment for illnesses that were previously incurable or challenging to control.
Adeno-associated virus (AAV), lentivirus, and herpes simplex virus are the three types of viral vectors that the U.S. FDA has approved for use in eight different therapeutic applications. Originally designed to treat uncommon illnesses, these treatments are now being used to treat more prevalent ailments.
As of February 2022, there were 120 viral-vector medicines during Phase II studies and 25 in late-stage development. It's anticipated that this pipeline will keep expanding.
Viral vectors are versatile for treating a variety of disorders because they have the ability to programmatically change gene expression. By replacing genes, they can treat uncommon monogenic diseases, and by managing gene expression they can treat diseases that affect a larger population.
As viral vector technologies advance, they are being applied to treat a broader spectrum of diseases, including rare monogenic disorders, cancers, infectious diseases, and more common conditions. This diversification of therapeutic applications necessitates the use of non-human primates (NHP) models to evaluate the safety and efficacy of these vectors across various indications, thereby driving demand in the viral vectors-based gene therapy for non-human primates market.
By type of vector, the Adeno-associated Vectors segment is projected to dominate the global viral vectors-based gene therapy for non-human primates market during the forecast period. The anticipated growth of the adeno-associated vectors segment is expected to be driven by the rising research and development activities focused on adeno-associated vectors for gene therapy in non-human primates throughout the forecast period.
For instance in May 2024, Capsida Biotherapeutics had announced new preclinical data supporting its gene therapy candidate, CAP-002, which aims to correct neurological phenotypes associated with genetic epilepsy caused by STXBP1 mutations. Capsida Biotherapeutics will present a poster titled "CAP-002: Systemic AAV Gene Therapy with Next Generation Capsids for Treatment of STXBP1 Encephalopathy".
The data indicates that a single intravenous infusion of CAP-002 leads to widespread expression of the STXBP1 gene in the brain, transducing up to 70% of neurons at therapeutically relevant doses in non-human primates.
Thus, the development highlights advancements in AAV vector technology, particularly in creating next-generation capsids that can efficiently transduce target cells. Such innovations are likely to attract attention from researchers and companies looking to harness AAVs for various therapeutic applications, thereby expanding the viral vectors-based gene therapy for non-human primates market
The Rhesus Macaques segment is projected to dominate the global viral vectors-based gene therapy for non-human primates during the forecast period. Rhesus Macaques are expected to dominate the viral vectors-based gene therapy for non-human primates market due to genetic similarity to humans.
Rhesus Macaques share approximately 93% of their DNA with humans, making them an ideal model for studying gene therapy's effects and efficacy. This genetic similarity allows for more accurate predictions of how gene therapies will behave in human patients, particularly in terms of immune response and the expression of therapeutic genes.
Moreover, Rhesus Macaques have been extensively used in biomedical research for decades, leading to a comprehensive understanding of their biology, genetics, and immune system. This wealth of knowledge makes it easier for researchers to design and interpret studies, enhancing the reliability and reproducibility of results.
Thus, the rhesus macaque's close genetic and physiological similarity to humans, extensive genetic variation, extensive use in biomedical research, and availability and adaptability make them dominant non-human primate models for viral vector-based gene therapy research.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America is expected to dominate the viral vectors-based gene therapy market for non-human primates due to increasing funding aimed at enhancing the supply of viral vectors.
North America is home to a robust biotechnology and pharmaceutical ecosystem, characterized by numerous companies and research institutions engaged in cutting-edge research and development activities.
For instance, in January 2023, Vector BioMed, a biomanufacturing company based in Gaithersburg, U.S., announced its launch and a first financing round worth U.S$ 15 Mn led by Viking Global Investors and Casdin Capital. The company, located at 910 Clopper Rd Suite 200S, specializes in the production of lentiviral vectors, which are critical for the development and commercialization of cell and gene therapies.
The funds will enable Vector BioMed to accelerate its commercial operations, providing partners with rapid access to high-quality lentiviral vectors for preclinical studies, clinical trials, and eventual commercialization.
Thus, the successful funding and launch of Vector BioMed will not only enhance the supply of lentiviral vectors but also stimulate growth in the North American viral vectors-based gene therapy for non-human primates market by facilitating research pertaining to therapies.
The leading players in the viral vectors-based gene therapy for non-human primates market include CRISPR Therapeutics, Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neuracle Genetics Inc., Beacon Therapeutics, REGENXBIO Inc., 4D Molecular Therapeutics and Rocket Pharmaceuticals, Inc.
Each of these players have been have been profiled in the viral vectors-based gene therapy for non-human primates industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 29.97 Mn |
| Forecast Value in 2034 | More than US$ 92.76 Mn |
| CAGR | 11.0% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2018-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global viral vectors-based gene therapy for non-human primates was valued at US$ 29.97 Mn in 2023
The viral vectors-based gene therapy for non-human primates is projected to reach more than US$ 92.76 Mn by the end of 2034
Increased research and development activities for viral vectors-based gene therapy for non-human primates, expanding therapeutic applications of viral vectors, and increasing funds for non-human primates models
The CAGR is anticipated to be 11.0% from 2024 to 2034
North America is expected to account for the largest share from 2024 to 2034
CRISPR Therapeutics, Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neuracle Genetics Inc., Beacon Therapeutics, REGENXBIO Inc., 4D Molecular Therapeutics, and Rocket Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Viral Vectors-based Gene Therapy for Non-human Primates Market
4. Market Overview
4.1. Introduction
4.1.1. Vector Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Recent Advancements in Viral Vectors Technology
5.2. List of Leading CROs offering Non-human Primates based Preclinical Testing Services
5.3. PORTER’s Analysis on Viral Vectors for Non-human Primates Industry
5.4. Key Shortlisting Metrics for End-users
5.5. Regional Distribution of Non-human Primate Preclinical Studies
5.6. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
5.7. Impact of COVID-19 Pandemic on Viral Vectors for Non-human Primates Industry
6. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vector Type, 2020-2034
6.3.1. Adenoviral Vectors
6.3.2. Adeno-associated Vectors
6.3.3. Retroviral Vectors
6.3.4. Lentiviral Vectors
6.3.5. Other Vectors
6.4. Market Attractiveness By Vector Type
7. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primate
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
7.3.1. Marmosets
7.3.2. Rhesus Macaques
7.3.3. Cynomolgus Monkey
7.3.4. Others
7.4. Market Attractiveness By Type of Non-human Primate
8. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Technology, 2020-2034
8.3.1. Genetic Disorders
8.3.2. Infectious Diseases
8.3.3. Oncological Disorders
8.3.4. Neurodegenerative Disorders
8.3.5. Other Disorders
8.4. Market Attractiveness By Technology
9. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Vector Type, 2020-2034
10.2.1. Adenoviral Vectors
10.2.2. Adeno-associated Vectors
10.2.3. Retroviral Vectors
10.2.4. Lentiviral Vectors
10.2.5. Other Vectors
10.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
10.3.1. Marmosets
10.3.2. Rhesus Macaques
10.3.3. Cynomolgus Monkey
10.3.4. Others
10.4. Market Value Forecast By Technology, 2020-2034
10.4.1. Genetic Disorders
10.4.2. Infectious Diseases
10.4.3. Oncological Disorders
10.4.4. Neurodegenerative Disorders
10.4.5. Other Disorders
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Vector Type
10.6.2. By Type of Non-human Primate
10.6.3. By Technology
10.6.4. By Country
11. Europe Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Vector Type, 2020-2034
11.2.1. Adenoviral Vectors
11.2.2. Adeno-associated Vectors
11.2.3. Retroviral Vectors
11.2.4. Lentiviral Vectors
11.2.5. Other Vectors
11.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
11.3.1. Marmosets
11.3.2. Rhesus Macaques
11.3.3. Cynomolgus Monkey
11.3.4. Others
11.4. Market Value Forecast By Technology, 2020-2034
11.4.1. Genetic Disorders
11.4.2. Infectious Diseases
11.4.3. Oncological Disorders
11.4.4. Neurodegenerative Disorders
11.4.5. Other Disorders
11.5. Market Value Forecast By Country, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Vector Type
11.6.2. By Type of Non-human Primate
11.6.3. By Technology
11.6.4. By Country
12. Asia Pacific Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Vector Type, 2020-2034
12.2.1. Adenoviral Vectors
12.2.2. Adeno-associated Vectors
12.2.3. Retroviral Vectors
12.2.4. Lentiviral Vectors
12.2.5. Other Vectors
12.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
12.3.1. Marmosets
12.3.2. Rhesus Macaques
12.3.3. Cynomolgus Monkey
12.3.4. Others
12.4. Market Value Forecast By Technology, 2020-2034
12.4.1. Genetic Disorders
12.4.2. Infectious Diseases
12.4.3. Oncological Disorders
12.4.4. Neurodegenerative Disorders
12.4.5. Other Disorders
12.5. Market Value Forecast By Country, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Vector Type
12.6.2. By Type of Non-human Primate
12.6.3. By Technology
12.6.4. By Country
13. Latin America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Vector Type, 2020-2034
13.2.1. Adenoviral Vectors
13.2.2. Adeno-associated Vectors
13.2.3. Retroviral Vectors
13.2.4. Lentiviral Vectors
13.2.5. Other Vectors
13.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
13.3.1. Marmosets
13.3.2. Rhesus Macaques
13.3.3. Cynomolgus Monkey
13.3.4. Others
13.4. Market Value Forecast By Technology, 2020-2034
13.4.1. Genetic Disorders
13.4.2. Infectious Diseases
13.4.3. Oncological Disorders
13.4.4. Neurodegenerative Disorders
13.4.5. Other Disorders
13.5. Market Value Forecast By Country, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Vector Type
13.6.2. By Type of Non-human Primate
13.6.3. By Technology
13.6.4. By Country
14. Middle East & Africa Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Vector Type, 2020-2034
14.2.1. Adenoviral Vectors
14.2.2. Adeno-associated Vectors
14.2.3. Retroviral Vectors
14.2.4. Lentiviral Vectors
14.2.5. Other Vectors
14.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
14.3.1. Marmosets
14.3.2. Rhesus Macaques
14.3.3. Cynomolgus Monkey
14.3.4. Others
14.4. Market Value Forecast By Technology, 2020-2034
14.4.1. Genetic Disorders
14.4.2. Infectious Diseases
14.4.3. Oncological Disorders
14.4.4. Neurodegenerative Disorders
14.4.5. Other Disorders
14.5. Market Value Forecast By Country, 2020-2034
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Vector Type
14.6.2. By Type of Non-human Primate
14.6.3. By Technology
14.6.4. By Country
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. CRISPR Therapeutics AG
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Voyager Therapeutics, Inc.
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. Sarepta Therapeutics, Inc.
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Neuracle Genetics
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Beacon Therapeutics
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. REGENXBIO Inc.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. 4D Molecular Therapeutics
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. Rocket Pharmaceuticals, Inc.
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments
List of Tables
Table 01: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
Table 02: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
Table 03: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 04: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
Table 05: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 06: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 07: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
Table 08: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 09: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 10: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
Table 11: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
Table 13: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
Table 14: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 15: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
Table 16: Asia Pacific Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
Table 18: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
Table 19: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 20: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
Table 21: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
Table 23: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
Table 24: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 25: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
Table 26: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
Table 28: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
Table 29: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 30: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
List of Figures
Figure 01: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, 2020-2034
Figure 02: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by Type of Vector, 2023
Figure 03: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by Type of Non-human Primate, 2023
Figure 04: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by Therapeutic Area, 2023
Figure 05: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by End-user, 2023
Figure 06: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, By Region, 2023
Figure 07: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
Figure 08: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Vector, 2023
Figure 09: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Vector, 2034
Figure 10: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
Figure 11: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Adenoviral Vectors, 2020-2034
Figure 12: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Adenoviral Vectors, 2023 and 2034
Figure 13: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Adeno-associated Vectors, 2020-2034
Figure 14: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Adeno-associated Vectors, 2023 and 2034
Figure 15: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Retroviral Vectors, 2020-2034
Figure 16: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Retroviral Vectors, 2023 and 2034
Figure 17: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Lentiviral Vectors, 2020-2034
Figure 18: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Lentiviral Vectors, 2023 and 2034
Figure 19: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Other Vectors, 2020-2034
Figure 20: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Other Vectors, 2023 and 2034
Figure 21: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
Figure 22: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Non-human Primate, 2023
Figure 23: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Non-human Primate, 2034
Figure 24: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
Figure 25: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Marmosets, 2020-2034
Figure 26: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Marmosets, 2023 and 2034
Figure 27: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Rhesus Macaques, 2020-2034
Figure 28: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Rhesus Macaques, 2023 and 2034
Figure 29: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Cynomolgus Monkey, 2020-2034
Figure 30: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Cynomolgus Monkey, 2023 and 2034
Figure 31: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Others, 2020-2034
Figure 32: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Others, 2023 and 2034
Figure 33: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 34: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Therapeutic Area, 2023
Figure 35: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Therapeutic Area, 2034
Figure 36: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Derivatives Type, 2024-2034
Figure 37: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Genetic Disorders, 2020-2034
Figure 38: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Genetic Disorders, 2023 and 2034
Figure 39: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Infectious Diseases, 2020-2034
Figure 40: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Infectious Diseases, 2023 and 2034
Figure 41: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Oncological Disorders, 2020-2034
Figure 42: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Oncological Disorders, 2023 and 2034
Figure 43: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Neurodegenerative Disorders, 2020-2034
Figure 44: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Neurodegenerative Disorders, 2023 and 2034
Figure 45: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Other Disorders, 2020-2034
Figure 46: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Other Disorders, 2023 and 2034
Figure 47: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
Figure 48: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, By End-user, 2023
Figure 49: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, By End-user, 2034
Figure 50: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
Figure 51: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2020-2034
Figure 52: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Pharmaceutical and Biotechnology Companies, 2023 and 2034
Figure 53: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Contract Research Organizations, 2020-2034
Figure 54: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Contract Research Organizations, 2023 and 2034
Figure 55: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Academic and Research Institutes, 2020-2034
Figure 56: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Academic and Research Institutes, 2023 and 2034
Figure 57: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Region, 2023 and 2034
Figure 58: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Region, 2023
Figure 59: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Region, 2034
Figure 60: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Region, 2023-2034
Figure 61: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 62: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country, 2023 and 2034
Figure 63: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country, 2024-2034
Figure 64: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
Figure 65: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
Figure 66: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
Figure 67: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
Figure 68: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 69: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 70: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
Figure 71: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
Figure 72: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 73: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 74: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 75: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
Figure 76: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
Figure 77: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
Figure 78: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
Figure 79: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 80: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 81: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
Figure 82: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
Figure 83: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 84: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 85: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 86: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
Figure 87: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
Figure 88: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
Figure 89: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
Figure 90: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 91: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 92: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
Figure 93: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
Figure 94: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 95: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 96: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 97: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
Figure 98: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
Figure 99: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
Figure 100: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
Figure 101: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 102: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 103: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
Figure 104: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
Figure 105: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 106: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 107: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 108: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
Figure 109: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
Figure 110: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
Figure 111: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
Figure 112: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 113: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 114: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
Figure 115: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Viral Vectors-Based Gene Therapy for Non-Human Primates Market
